Multiple Oncogenic Pathway Signatures Show Coordinate Expression Patterns in Human Prostate Tumors
Chad J. Creighton · 2008
Read Multiple Oncogenic Pathway Signatures Show Coordinate Expression Patterns in Human Prostate Tumors by Chad J. Creighton (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001816.txt.
Introduction
Chad J. Creighton analyzed gene activity patterns in prostate tumors in a 2008 PLOS ONE research article. Gene transcription patterns linked to activation of oncogenes had been generated in experimental models. The oncogenes include Myc, c-Src, beta-catenin, E2F3, H-Ras, and HER2, and patterns also covered the cell cycle and androgen signaling.
Creighton asked whether these pathway signatures show coordinate expression patterns in human prostate tumors: whether pathways turn on together in real patients. The full text gives the tumor data sets and the signature correlations. Coordinated pathways suggest combination drug strategies, since blocking one route may leave its partners still driving the tumor.
Catalog record
| CREATOR | Chad J. Creighton |
|---|---|
| YEAR | 2008 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001816
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Multiple Oncogenic Pathway Signatures Show Coordinate Expression Patterns in Human Prostate Tumors Authors: Chad J. Creighton Published: 2008, PLOS ONE DOI: 10.1371/journal.pone.0001816 ABSTRACT Gene transcription patterns associated with activation of oncogenes Myc, c-Src, beta-catenin, E2F3, H-Ras, HER2, EGFR, MEK, Raf, MAPK, Akt, and cyclin D1, as well as of the cell cycle and of androgen signaling have been generated in previous studies using experimental models. It was not clear whether genes in these “oncogenic signatures” would show coordinate expression patterns in human prostate tumors, particularly as most of the signatures were derived from cell types other than prostate. The above oncogenic pathway signatures were examined in four different gene expression profile datasets of human prostate tumors (representing ∼250 patients in all), using both Q1-Q2 and one-sided Fisher's exact enrichment analysis methods. A significant fraction (∼5%) of genes up-regulated experimentally by Myc, c-Src, HER2, Akt, or androgen were co-expressed in human tumors with the oncogene or biomarker corresponding to the pathway signature. Genes down-regulated experimentally, however, did not show anticipated patterns of anti-enrichment in the human tumors. Significant subsets of the genes in these experimentally-derived oncogenic signatures are relevant to the study of human prostate cancer. Both molecular biologists and clinical researchers could focus attention on the relatively small number of genes identified here as having coordinate patterns that arise from both the experimental system and the human disease system. INTRODUCTION Cancer is a disease characterized by DNA damage and widespread deregulation of cell signaling and gene transcription. Genes with roles in cancer can be broadly grouped into oncogenes, tumor supressors, and DNA damage-associated genes. Oncogenes promote cancer by over-expression or hyper-activation. The molecular pathways leading to oncogenesis and tumor progression are diverse [1] . Much progress has been made in the past 30 years in defining these pathways at the level of signal transduction involving protein-to-protein interaction. However, signal transduction leads through the chain of events to transcriptional regulation of a specific set of genes [1] . With the advent of global gene expression profiling technology within the last ten years, we can now more readily examine oncogenic pathways at the level of gene transcription. Through the use of experimental models such as cell cultures or transgenic mice, one may turn up the expression or activity of a specific gene and observe which genes are regulated as a result. Here an oncogenic pathway signature will be defined to mean a set of genes that show a specific pattern of up- or down-regulation when a given pathway associated with oncogenesis is activated. Oncogenic signatures observed experimentally have potential use for inferring pathway deregulation in human tumors. In a seminal study by Lamb et al . [2] , a set of genes induced by cyclin D1 in an in vitro model were found to be co-expressed as a group with cyclin D1 mRNA in multiple expression profile datasets of human tumors of various types. In a recent study by Bild et al . [3] , gene signatures of Myc, Ras, E2F3, Src, and beta-catenin defined in vitro were used to predict Ras mutation status in human lung tumors and to predict the response of a panel of breast cancer cell lines to Src or Ras inhibitors. In another study by Creighton et al . [4] , a signature of the MAP kinase pathway was defined from gene expression profiles of ErbB-2 (HER2), EGFR, Raf, and MEK in MCF-7 cells; this MAPK signature was found to share extensive similarities with signatures of ER-negative human breast cancer, which commonly has hyper-activated MAPK. The oncogenic pathway signatures described above were generated from gene expression profiling of breast cell cultures. One question addressed here was which signatures could be considered relevant to human cancers of a different cell type from breast, in other words, whether genes associated with a given pathway in an experimental model show patterns of expression in human tumors that would be consistent with that pathway association. In the case of the Lamb cyclin D1 signature, human tumors of various cell types (including breast and prostate) that had high levels of cyclin D1 were found to express high levels of genes in the cyclin D1 signature [2] . This present study explored whether oncogenic signatures from other studies followed similar patterns in human prostate cancer. The focus of this study was in prostate cancer, as it is the most commonly occurring cancer in males in the United States, and as there were several profile datasets of human prostate cancer that were publically available. Here, mRNA signatures of oncogenes Myc, c-Src, beta-catenin, E2F3, H-Ras, HER2, EGFR, MEK, Raf, MAPK, Akt, and cyclin D1, along with signatures of the cell cycle and of androgen signaling, were collected from eight previously published studies. As there have been multiple profiling studies of human prostate tumors [5] – [8] , one can look for gene expression patterns that are common across independent datasets [9] . These oncogenic signatures were therefore examined in four different profile datasets of prostate tumors. As mentioned above, the aim of this study was to determine if these experimentally-defined oncogenic pathway signatures were relevant to human prostate cancer. The specific hypothesis tested was that human prostate tumors with (relatively) high mRNA levels of a given oncogene should also show high levels of the group of genes found over-expressed in the experimental setting when the same oncogene is turned up. One important outcome of this analysis was a catalog of the genes from a given experimentally-derived pathway signature that also had expression patterns considered relevant to the human tumors, which provides a resource for future functional studies. RESULTS Using gene expression profile datasets of cell culture and mouse models from previously published studies (listed in Table 1 ), gene signatures of 14 different oncogenic pathways were defined. These signatures are described in Table 2 and shown graphically in Figure 1 . The pathways represented by these signatures were the following: (1) Myc, c-Src, beta-catenin, E2F3, and H-Ras, from the study by Bild et al . [3] ; (2) erbB-2 (HER2), EGFR, MEK, Raf, and MAPK from Creighton et al . [4] ; (3) the cell cycle from Whitfield et al . [10] ; (4) androgen receptor (AR) signaling, from Deprimo et al . [11] ; (5) AR signaling, from Chen et al . [12] ; (6) Myc, from Coller et al . [13] ; (7) cyclin D1, from Lamb et al . [2] ; and (7) Akt, from Majumder et al . [14] . The unique named genes involved in each of these signatures are listed in Supplementary Data File S1 . RNA profiling datasets were collected from various published studies (described in Table 2 ) in which a particular pathway was activated in an experimental model. Expression patterns are represented as a color map. Each row represents a gene; each column represents a sample. The level of expression of each gene in each sample is represented using a yellow–blue color scale (yellow: high expression). Pathways represented are the following: (A) Myc, c-Src, beta-catenin, E2F3, and H-Ras, from the study by Bild et al . [3] ; (B) erbB-2 (HER2), EGFR, MEK, Raf, and MAPK from Creighton et al . [4] ; (C) the cell